Good morning :)
$
₹
XTL Biopharmaceuticals Ltd ADR

XTL Biopharmaceuticals Ltd ADR

XTLB

NASDAQ
Asset Logo

XTL Biopharmaceuticals Ltd ADR

XTLB

NASDAQ
$1.652.64% (-0.04)
$
₹
$1.652.64% (-0.04)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Micro Cap

With a market cap of $4.2M the stock is ranked 5980

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

1.89
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-0.36
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

0
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Company Profile

Company Profile

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Herzliya, Israel.
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Herzliya, Israel.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
49.14
49.14
1Y Return
32.47%
32.47%
Buy Reco %
79.31
79.31
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
28.64
28.64
1Y Return
56.57%
56.57%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
36.15%
36.15%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
35.59
35.59
1Y Return
30.2%
30.2%
Buy Reco %
81.25
81.25
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
21.51
21.51
1Y Return
48.38%
48.38%
Buy Reco %
67.85
67.85
Compare with Peers

Forecast

Forecast

empty forecast

Forecast data is currently unavailable

Forecast data is currently unavailable

Price

Price Upside

Revenue

Revenue Growth

Earnings

Earnings Per Share

Financials

Financials

Income

Balance Sheet

Cash Flow

289
-255
Q1 2025
Q2 2025
Q4 2025
Q1 2026
Revenue
Net Income
Financial YearQ3 2023Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q4 2025Q1 2026
Total Revenue0000162289289---
Net Income-215-0.28485-704-553-255-255---
Net Profit Margin-----341.35%-88.23%-88.23%---
See CostsAll values in $ Thousand

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
XTL Biopharmaceuticals Ltd ADR -1.890
AbbVie Inc49.1450.450.58
Amgen Inc28.6421.552.77
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare XTLB with any stock or ETF
Compare XTLB with any stock or ETF
Comparing from
XTLB
ABBV
AMGN
Loading...

Frequently asked questions

  1. XTL Biopharmaceuticals Ltd ADR (XTLB) share price today is $1.65 as of November 6, 2026 at 12:09 AM IST. The stock touched a day high of $1.73 and a day low of $1.55.

  2. XTL Biopharmaceuticals Ltd ADR stock trades on NASDAQ under the ticker symbol XTLB.

  3. XTL Biopharmaceuticals Ltd ADR's market capitalization is $4.23M as of November 6, 2026 at 12:09 AM IST.

  4. XTL Biopharmaceuticals Ltd ADR's price-to-earnings (P/E) ratio is N/A as of November 5, 2026.

  5. XTL Biopharmaceuticals Ltd ADR's price-to-book (P/B) ratio is 1.89 as of November 5, 2026.

  6. Yes, You can buy XTL Biopharmaceuticals Ltd ADR shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy XTL Biopharmaceuticals Ltd ADR shares in three steps: 1. Search XTL Biopharmaceuticals Ltd ADR on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since XTL Biopharmaceuticals Ltd ADR trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in XTL Biopharmaceuticals Ltd ADR (XTLB) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 6.0422 shares at the current price of $1.65.

Loading...